{"ticker": {"uuid": "30cfac57-4773-4d98-8fcb-bf4b9058e783", "symbol": "LUNG", "name": "Pulmonx\u00a0Corp", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Medical Devices"}, "articles": [{"title": "Pulmonx to Report Second Quarter 2026 Financial Results on July 29, 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxPemxweWlKeDByaklqVm5tNlMxVGZfT05Db0hWbkJBb0E5ZVlaeHUwN0hUZDY0cUplcmljdWx0TzZ0MzFKcjhPSDJMQ1V2OTdub2dBNEY3cmRKM1RnOEtIMzdLTEVOMEtYbWduOUhaMjJ3NElrbGd5cXYtWTYyREVzWmF1bldxUnZRczhiby1ycUIwZW9uZUVNcE9JQ0dOc1FKZzFyWEc5NktiTHg1UFBnQlhuV0hoZDVuSkd4RkNlZlJIdw?oc=5", "source_name": "marketscreener.com", "published_at": "2026-07-15T20:05:05+00:00", "published_display": "15 Jul 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmonx Sets July 29 Webcast to Discuss Second-Quarter Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNcFhRTWNfTlZGY2gtZUIzaWxSMFkwTHVMaVcxZkpkQm5rQXppVmVMY0dVUGRQS0xVOElINDY5THBHbGFHQUZaMTN4WU1qYTd4MFlYMFFGR3lLdHdCdEk5dVJDSXllZ09LNnVKVlRiYlY3RmhteWN2cnQzc0phdFM4LXRvc1ljdUdRbE9ZTnNBbjc3cU1seUhxZEEtT3JHWjZXVVNIdG5MX3c2RlNvSU9ZaEoyWlBOZFdseGQzWEZ3?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T20:05:00+00:00", "published_display": "15 Jul 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Reflecting On Medical Devices & Supplies - Specialty Stocks\u2019 Q1 Earnings: Integer Holdings (NYSE:ITGR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNUFd1SUpRcWlCdEFjU1YzNTZkdjBfRkwyY2lBYjh1ZXZlZTlyVlpWSWx1bExvckFrNHNhUEdVTGNFWUxaMkVDZUV2c2hPS1h2YVhNSHNsVzFYNUFrNHBnRVM1STRsa2Zmb0VXeEQ4UFRGNDBOWXZfWVU5VFUyQ3JZZm9KamZMWXVDSEtNMWwyVktpaEZfRjVNU1BYaWJ3NnpNUmRyMEpsSzBXdw?oc=5", "source_name": "Market source", "published_at": "2026-07-14T18:07:11+00:00", "published_display": "14 Jul 2026 18:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Yun-Lung Chen Sells 5,958 Shares of Ambarella (NASDAQ:AMBA) Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxQbTRSd0JCZFZEcWxoSF9pWmkzNW9KNVhuQXNBaGJZUW10QjJuUjF1SjhOcXFrYm56RkI4N2w4WlZURWpROE5NbUxHY043RTZmNjg2OHkwS0NNRlN0ZlppSkwyVlJyRktpemtYQ2JjSWZmelBFS1hOVlNEMjZDWTd4Nm1UclVKd2MwbGFsUGxoX3Fhb0ZXTUpScmtDM2w2Wm0wMVJHbVRjNlpKbTk5YTRFYmlaeVdlQQ?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-10T21:09:06+00:00", "published_display": "10 Jul 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmonx (NASDAQ:LUNG) Sparks Fresh Penny Stock Buzz", "summary": "Pulmonx (NASDAQ:LUNG) is attracting attention as a penny stock due to its focus on severe emphysema treatment. The company's key products, the Zephyr Endobronchial Valve and the Chartis system, are highlighted for their role in improving lung function in affected patients. This r", "url": "https://kalkinemedia.com/us/stocks/penny/pulmonx-nasdaqlung-sparks-fresh-penny-stock-buzz", "source_name": "Kalkine Media", "published_at": "2026-07-09T20:45:19", "published_display": "09 Jul 2026 20:45", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmonx Corp highlights lung device strategy as a specialized medtech player", "summary": "Pulmonx Corp positions itself as a specialized medical technology company focusing on minimally invasive devices for severe emphysema and chronic respiratory conditions. Its business model centers on bronchoscopic procedures, generating revenue from implantable devices and associ", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/pulmonx-corp-highlights-lung-device-strategy-as-a-specialized-medtech/69716357", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T19:32:00", "published_display": "07 Jul 2026 19:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Pulmonx Corp. \u2013 LSX:A2P1AF", "summary": "This page from TradingView provides financial information for Pulmonx Corp. under the ticker LSX:A2P1AF. It focuses on the enterprise value to EBITDA forward metric, but the actual data values are not visible in the provided content. The page also includes various navigation and ", "url": "https://www.tradingview.com/symbols/LSX-A2P1AF/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T06:09:24", "published_display": "05 Jul 2026 06:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Pulmonx Corp. \u2013 LSX:A2P1AF", "summary": "This article focuses on the \"Enterprise value to EBIT forward\" metric for Pulmonx Corp. (LSX:A2P1AF). It appears to be a financial data snippet from TradingView, providing an overview of a specific valuation ratio for the company's stock. The content points to financial data avai", "url": "https://www.tradingview.com/symbols/LSX-A2P1AF/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T04:39:39", "published_display": "05 Jul 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Pulmonx Corp. \u2013 LSX:A2P1AF", "summary": "This article provides the \"Price to earnings forward\" valuation metric for Pulmonx Corp. (LSX:A2P1AF). It indicates the value and change of this financial data point over a period. The information is presented within the context of TradingView's platform, which offers various fin", "url": "https://www.tradingview.com/symbols/LSX-A2P1AF/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T02:10:12", "published_display": "05 Jul 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Pulmonx Corp. \u2013 DUS:4NI", "summary": "This article provides the \"Price to earnings forward\" data for Pulmonx Corp. (DUS:4NI) on the TradingView platform. It details the company's financial information, presented within the context of the D\u00fcsseldorf Stock Exchange. The content is primarily a data page on a financial p", "url": "https://www.tradingview.com/symbols/DUS-4NI/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T01:39:39", "published_display": "05 Jul 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Pulmonx Corp. \u2013 DUS:4NI", "summary": "This page from TradingView provides financial information for Pulmonx Corp. (4NI) listed on the Dusseldorf Stock Exchange, specifically focusing on its forward price-to-sales ratio. The article includes standard market data and copyright information, indicating that the market fo", "url": "https://www.tradingview.com/symbols/DUS-4NI/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T01:10:12", "published_display": "05 Jul 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmonx Corp highlights its respiratory device portfolio as investors assess long-term growth prospects", "summary": "Pulmonx Corp (PULM) focuses on developing minimally invasive medical devices for severe emphysema and other chronic obstructive pulmonary diseases, targeting a significant unmet medical need. The company's business model involves selling specialized devices to healthcare provider", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/pulmonx-corp-highlights-its-respiratory-device-portfolio-as-investors/69681305", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-03T15:40:31", "published_display": "03 Jul 2026 15:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmonx Corp. Actuals & Estimates (NASDAQ:LUNG)", "summary": "This article provides financial actuals and estimates for Pulmonx Corporation (NASDAQ: LUNG), including its current stock price, historical performance, analyst forecasts, and company financials. It details the company's market capitalization, last quarter's earnings and revenue,", "url": "https://www.tradingview.com/symbols/NASDAQ-LUNG/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T01:11:28", "published_display": "26 Jun 2026 01:11", "sentiment": "negative", "sentiment_pct": 30, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmonx Corp (LUNG) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Pulmonx Corp (LUNG) has a stable financial status but low operating efficiency, ranking 142 out of 204 in the Healthcare Equipment & Supplies industry with a financial score of 6.69. The company's latest quarterly revenue decreased by 8.66% year-over-year to $20.59 million, and i", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lung/financial-health", "source_name": "TradingKey", "published_at": "2026-06-23T23:40:47", "published_display": "23 Jun 2026 23:40", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmonx Corp (LUNG) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Pulmonx Corp (LUNG), highlighting its price momentum score of 5.32 within the Healthcare Equipment & Supplies industry. It details the stock's current trading range between a resistance level of $1.59 and a support level of $1.09, sug", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lung/technical", "source_name": "TradingKey", "published_at": "2026-06-18T22:09:19", "published_display": "18 Jun 2026 22:09", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmonx Corp (LUNG) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Pulmonx Corp (LUNG), highlighting its current earnings forecast score, average price target of $4.50, and analyst ratings. Based on 5 analysts, the stock has a \"Buy\" trend. The article also includes expected revenue and EPS for upcom", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lung/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T11:09:47", "published_display": "18 Jun 2026 11:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmonx Corp (LUNG) Institutional Confidence", "summary": "Pulmonx Corp (LUNG) has an institutional shareholding score of 7.00, placing it 79th out of 204 in the Healthcare Equipment & Supplies industry. The institutional shareholding proportion increased by 10.02% quarter-over-quarter to 87.40%. James Simons is noted as the largest inst", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lung/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T11:09:47", "published_display": "18 Jun 2026 11:09", "sentiment": "positive", "sentiment_pct": 69, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmonx Corp (LUNG) Valuation: PE, PB & Fair Value Analysis", "summary": "The article provides a valuation analysis for Pulmonx Corp (LUNG), noting its current valuation score is 7.71, ranking 137 out of 204 in the Healthcare Equipment & Supplies industry. It highlights the company's P/E ratio of -0.97, which represents a decrease from its recent high ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lung/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T10:09:48", "published_display": "18 Jun 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmonx Corp (LUNG) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a revenue breakdown for Pulmonx Corp (LUNG), detailing its revenue by geographical region for the fiscal year 2023. The United States contributed the largest portion of revenue at 63.01% ($57.02 million), followed by Europe, Middle-East and Africa (\"EMEA\") a", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lung/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T21:09:21", "published_display": "17 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmonx Corp (LUNG) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Pulmonx Corp's (LUNG) dividend and stock split history, noting that no dividend data or stock split data is available. It shows the current stock price, market cap, and links to various company and market analysis sections on the TradingKey pl", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lung/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T21:09:21", "published_display": "17 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks Q1 Earnings: ICU Medical (NASDAQ:ICUI) Firing on All Cylinders", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNTWR3bzJReVB0UTNleWx6WDlmRW1rYmpLdkptZHdadzVERk1hTzdEV0M1Z2tuRUx2cldOT2d3WlVDank5Y01EWWFfWXdWNkJFdkNFcnhjMjdCQ1Y2aFBVbndiNXVBY0F5dDRpU2Fla25fVWRTUlNROXFwYXNXT2czUm5Nbl9QUFhFTEhHd1ZKTzJUSzhJWjN6QnNNUEVBTVEyR0l6YkZacUVsdw?oc=5", "source_name": "Market source", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "[Form 4] Pulmonx Corp Insider Trading Activity", "summary": "Pulmonx Corp director Thomas William Burns has been granted 40,000 Restricted Stock Units (RSUs) as compensation, not through a market purchase. These RSUs, valued at $0.0000 per share, will vest on the earlier of one year from the June 5, 2026 grant date or the date of the Annua", "url": "https://www.stocktitan.net/sec-filings/LUNG/form-4-pulmonx-corp-insider-trading-activity-a7293e34ec44.html", "source_name": "Stock Titan", "published_at": "2026-06-10T18:39:13", "published_display": "10 Jun 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmonx (LUNG) director receives 40,000-share RSU stock grant", "summary": "Pulmonx Corp director Dana G. Mead Jr. was granted 40,000 Restricted Stock Units (RSUs) which are payable in common stock. This is an equity compensation award, not an open-market purchase, with a grant price of $0.00 per share. These RSUs will vest on the earlier of June 5, 2026", "url": "https://www.stocktitan.net/sec-filings/LUNG/form-4-pulmonx-corp-insider-trading-activity-7432e390c79e.html", "source_name": "Stock Titan", "published_at": "2026-06-10T06:40:14", "published_display": "10 Jun 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LUNG SEC Filings - Pulmonx Corp 10-K, 10-Q, 8-K Forms", "summary": "This page provides access to SEC filings for Pulmonx Corporation (LUNG), a medical technology company. It includes 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider trading forms. The filings detail the company's financial results, governance, compensa", "url": "https://www.stocktitan.net/sec-filings/LUNG/page-5.html", "source_name": "Stock Titan", "published_at": "2026-06-10T03:39:51", "published_display": "10 Jun 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Don't Ignore The Insider Selling In Pulmonx", "summary": "Pulmonx Corporation's CEO and President, Glendon French, recently sold US$87k worth of stock at US$1.55 per share, following an earlier sale of US$97k below the current price. Insiders own 5.1% of Pulmonx shares, worth approximately US$3.3m, but there have been no insider purchas", "url": "https://www.sahmcapital.com/news/content/dont-ignore-the-insider-selling-in-pulmonx-2026-06-07", "source_name": "Sahm", "published_at": "2026-06-07T22:11:00", "published_display": "07 Jun 2026 22:11", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmonx (LUNG) officer sells 14,497 shares to cover RSU tax withholding", "summary": "Pulmonx Corp's Chief Science & Technology Officer, Radhakrishnan Srikanth, sold 14,497 shares of common stock on June 1, 2026, across four transactions at $1.54 per share. These sales totaling $22,325 were made exclusively to cover tax withholding obligations stemming from the ve", "url": "https://www.stocktitan.net/sec-filings/LUNG/form-4-pulmonx-corp-insider-trading-activity-533f2da6b3c1.html", "source_name": "Stock Titan", "published_at": "2026-06-04T16:09:33", "published_display": "04 Jun 2026 16:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmonx general counsel David Lehman sells $22,474 in stock", "summary": "David Aaron Lehman, General Counsel at Pulmonx Corp, sold 14,594 shares of company stock worth $22,474 on June 1, 2026, to cover tax obligations from vested RSUs. This transaction occurred as Pulmonx faces financial challenges, including quickly burning through cash and remaining", "url": "https://m.uk.investing.com/news/insider-trading-news/pulmonx-general-counsel-david-lehman-sells-22474-in-stock-93CH-4712760?ampMode=1", "source_name": "Investing.com UK", "published_at": "2026-06-04T04:40:11", "published_display": "04 Jun 2026 04:40", "sentiment": "negative", "sentiment_pct": 30, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmonx (LUNG) CCO sells shares to cover RSU tax obligations", "summary": "Pulmonx Corp's Chief Commercial Officer, Geoffrey Beran Rose, sold 8,023 shares of common stock at $1.54 per share on June 1, 2026. These sales were conducted to cover tax withholding obligations associated with the vesting of his Restricted Stock Units from 2023, 2024, 2025, and", "url": "https://www.stocktitan.net/sec-filings/LUNG/form-4-pulmonx-corp-insider-trading-activity-a3a1fee41177.html", "source_name": "Stock Titan", "published_at": "2026-06-03T20:09:29", "published_display": "03 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmonx (LUNG) General Counsel sells 14,594 shares to cover RSU tax obligations", "summary": "Pulmonx Corp General Counsel David Aaron Lehman sold 14,594 shares of common stock at $1.54 per share on June 1, 2026. These sales were executed in four transactions solely to cover tax withholding obligations arising from the vesting of Restricted Stock Units granted between 202", "url": "https://www.stocktitan.net/sec-filings/LUNG/form-4-pulmonx-corp-insider-trading-activity-6f9d8660cef2.html", "source_name": "Stock Titan", "published_at": "2026-06-03T20:09:29", "published_display": "03 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmonx (LUNG) CEO logs 56K-share sale tied to RSU tax withholding", "summary": "Pulmonx Corp CEO Glendon E. French III sold 56,149 shares of common stock on June 1-2, 2026, at prices between $1.54 and $1.57 per share. These sales were made to cover tax withholding obligations related to the vesting of Restricted Stock Units (RSUs) granted on March 1, 2023, a", "url": "https://www.stocktitan.net/sec-filings/LUNG/form-4-pulmonx-corp-insider-trading-activity-cb3a2e50bf58.html", "source_name": "Stock Titan", "published_at": "2026-06-03T20:09:29", "published_display": "03 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "17 Pulmonx hires receive 84,300 RSUs in Nasdaq inducement plan", "summary": "Pulmonx (Nasdaq:LUNG) has granted equity awards totaling 84,300 Restricted Stock Units (RSUs) to 17 new employees hired in the first two quarters of 2026. These awards, issued under its 2025 Inducement Plan, are subject to a four-year vesting schedule, with one-fourth vesting on ", "url": "https://www.stocktitan.net/news/LUNG/pulmonx-corporation-announces-inducement-grants-under-nasdaq-listing-zj3qliqrqhkw.html", "source_name": "Stock Titan", "published_at": "2026-06-02T15:09:50", "published_display": "02 Jun 2026 15:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "Pulmonx Corporation announced that it granted equity awards to 17 new employees on June 1, 2026, under its 2025 Inducement Plan. These awards, totaling 84,300 restricted stock units, were approved by the Compensation Committee as an inducement for employment, in compliance with N", "url": "https://www.manilatimes.net/2026/06/02/tmt-newswire/globenewswire/pulmonx-corporation-announces-inducement-grants-under-nasdaq-listing-rule-5635c4/2356240/amp", "source_name": "The Manila Times", "published_at": "2026-06-01T20:09:01", "published_display": "01 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Review: Medical Devices & Supplies - Diversified Stocks Led by Baxter (NYSE:BAX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNYjhBT3BjMWFVU1FFUUFub0d6QUVEUTdwWFVMRG5fN2dHSnIxTXQwMWU1aElKaEV1a2dYLTFHMlBzMVFTZEtaX0xRRDFhZDl1WFdDYWF2RDZxOG9SRUtycmZacTRzM2FaaEU3OS1GZ2taLWtSMjZ4enhVNHRvdzJsanp4cEhNcGI1dllTOUplWUUtNjRlRm85MlFEVWxSYUV2d243QVd3?oc=5", "source_name": "Market source", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Medical Devices & Supplies - Diversified Stocks Q1 Results: Benchmarking Stryker (NYSE:SYK)", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxNb1NaVXV6UW42emtDUzh5ckhKVjc2X29fSlFRRDVIVnRLWXpoWEYxUnVKNGZuLVN6ZWhxVno1SGluMEdLcmNrOGN1ZjlsWFpVRWxYbW9aYy01VFFpVzlncWtBYzF3YkJfNzhwTi1BcWlpVF9pUTU4QnNGWkJSV3YwRXVCUzk2Z2NUMWFjVkJOV2hSbFRrRnIxSWxNUGRoQmhQeDVBRjhYSnhvMDJqUThjYjBHRjhTRTBDdDZJd1k3LU5DTjU2cUx6TXFNdHhVS1FfdlFmaWZLNk41cFk?oc=5", "source_name": "StockStory", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Pulmonx (LUNG) Q1 2026 Earnings Transcript", "summary": "", "url": "https://finance.yahoo.com/m/20552afe-2c36-3531-a10b-e88c4489fc7f/pulmonx-%28lung%29-q1-2026.html", "source_name": "Motley Fool", "published_at": "2026-04-30T16:25:20+00:00", "published_display": "30 Apr 2026 16:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmonx Corporation Q1 2026 Earnings Call Summary", "summary": "", "url": "https://finance.yahoo.com/m/b0a2f218-62a9-3f4f-a795-a3e923c01a95/pulmonx-corporation-q1-2026.html", "source_name": "Moby", "published_at": "2026-04-30T12:30:00+00:00", "published_display": "30 Apr 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmonx Corp (LUNG) Q1 2026 Earnings Call Highlights: Navigating Challenges with Strategic ...", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/pulmonx-corp-lung-q1-2026-071730915.html", "source_name": "GuruFocus.com", "published_at": "2026-04-30T07:17:30+00:00", "published_display": "30 Apr 2026 07:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmonx Q1 Earnings Call Highlights", "summary": "", "url": "https://finance.yahoo.com/m/b6392ff6-2067-3349-9cf8-609646793e13/pulmonx-q1-earnings-call.html", "source_name": "MarketBeat", "published_at": "2026-04-29T21:50:17+00:00", "published_display": "29 Apr 2026 21:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmonx Corporation (LUNG) Reports Q1 Loss, Tops Revenue Estimates", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/pulmonx-corporation-lung-reports-q1-214506050.html", "source_name": "Zacks", "published_at": "2026-04-29T21:45:06+00:00", "published_display": "29 Apr 2026 21:45", "sentiment": "negative", "sentiment_pct": 42, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmonx Reports First Quarter 2026 Financial Results", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/pulmonx-reports-first-quarter-2026-200500616.html", "source_name": "GlobeNewswire", "published_at": "2026-04-29T20:05:00+00:00", "published_display": "29 Apr 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmonx Corporation (LUNG) Stock Falls on Q1 2026 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxPZWM5SnJLbEpRTWNfRFM5SW9sMlVsV3E1U2VPNW1OcTV1Y1VmdkI4eVdNWnpjX0tCY29TcDhOWWJoWlQwQmtjVUdsejl5YXpoNGR3MHhVd19MR0xBZXBicmI4T1lxSjVkNTlxZmFjcHdmVi1NN09aRDZXZHd0UzBYVGxOYVJob3R4bi1WNTd2RWRPcU5IeXc?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 22, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmonx to Present at the Bank of America Securities 2026 Health Care Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/pulmonx-present-bank-america-securities-200500916.html", "source_name": "GlobeNewswire", "published_at": "2026-04-28T20:05:00+00:00", "published_display": "28 Apr 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmonx to Detail Growth Strategy at Key Investor Conference", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxQSE5OQXlJd2o5VkVyZ0VWQW9HQjA0QlVEeHc2ZzhfLUtfa05PUFFkMGo1dmg0RDE0M0dfcDM5LVZIcUNlcGJqN2toRDR0NlI1NzdsTkppTU52djBPMjFZOWdCYUdWemJQRzdGc0VlM2xndXdPS0U3bzd0NDRJN2tfVzY0MHhJeGRqR0JWbGEtYWtMbnJxclVhOQ?oc=5", "source_name": "BriefGlance", "published_at": "2026-04-28T07:00:00+00:00", "published_display": "28 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmonx webcast set for May 12 Bank of America health conference", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOYy05MTYzMlpRVG1BYVU1djBTcnc4YVNrUGN4NVh4SWNJb2JRSzMteEpuTlNDalJqZU12YlNzSEpIVnFtelhlbmxtSUJpMEJWMWlqZ3VTY0xuemw5ZzRua3M5NXBLOWhLbExpNXFRSFB6dzMwOTdyWEtjT2dLckRpWi1pc1k5VHVicVpKcGdqc3BYUnBabkNHQ3pyQTFoT2dwSFotN2VQR0lVemZEb0RaX08tLXV5TE5qbjZN?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-28T07:00:00+00:00", "published_display": "28 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Medical Devices & Supplies - Specialty Q4 Earnings: Globus Medical (NYSE:GMED) is the Best in the Biz", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNcDFMNmtOVk5PVFM1YzMyVWhyS3dwY0dMVE5BUng5U1JoOFRQMXNFRGxTMmlBRUV0bENRSWFXTDFZOXBQQkNZT0FOWDdISjRCcU9pRV9aNHBwUVBuZkVEV3g1dklVY19KOE9iWUNpNUtMS2NuOEcxMlQtNU8ydURybEdkNVoxZThWLTBIeVhid2NjQ0FWWTUzb2dxcmlMQThFQmZ4bldzRjcwUQ?oc=5", "source_name": "Market source", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "How The Pulmonx (LUNG) Investment Narrative Is Resetting Around A Lower Target And Execution Risk", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/pulmonx-lung-investment-narrative-resetting-150530295.html", "source_name": "Simply Wall St.", "published_at": "2026-04-19T15:05:30+00:00", "published_display": "19 Apr 2026 15:05", "sentiment": "negative", "sentiment_pct": 34, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Medical Devices & Supplies - Imaging, Diagnostics Stocks\u2019 Q4 Earnings: Hologic (NASDAQ:HOLX) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOdkl6Ym5HSGVhZUw3TzNlNVFPSjdDQk5NMTVSRW1xVnh3RE5RNU9veVR0TDEtcVdxV3BYelI0bWxCYXgwWmhZQ3ZONUVRdlhjX0ZiMklRVDJQRXN0LXcyVWVnb0E2WTdiRERtZk1pNGpmVHhWbHl5eHJuNnBtTDVPMUluTmRsQUVqYjNlSl8zR3djclh0X2ZIc1gzTlhPanR6ZTJ6R1FB?oc=5", "source_name": "Market source", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "How The Pulmonx (LUNG) Investment Story Is Shifting After Q4 And New Guidance", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNSHo4SFM5NzJrbEI1OC1HazJXOXBLT3hhTldYZDY1NWpiLWlIR00zR2xNWmZybDh1YmZmTTlnTjRqM1VRRlB0SlY0VmY2dHA0Z3JZd2tVM282X1dVUGtHUWQ2RzV4OXJxVE02UDc3TG1wdlhKVGlKamptR3BuUGhuWVRnemdnSkZYTnBTUXJIVjFPZHRyc3ZIVmFqWTJobGQxS1hvaWR3?oc=5", "source_name": "Market source", "published_at": "2026-04-04T07:00:00+00:00", "published_display": "04 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Artivion (NYSE:AORT) Vs The Rest Of The Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPaTgxS3dlMlZ5dDZ3dFlGdG9yRWFubkVqMk9yOTN6OEtyemljTWJGYUcxb2pmd2FTNTFKMlhIVGxrdlJsOG5iY1VQaXE4ZmYycTVpRkE0aEJ3QlB5bC10ZXN2dTFYNy0wRWdrNURVUlo5dEMzQklxQ0kwQTRkOXE0UDdTMkRGRWxoQ1ZQeG4tOXNONlR2SkxfZW5ST1B6N3BBeFZZQ3N1UFE?oc=5", "source_name": "Market source", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: CooperCompanies (NASDAQ:COO) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOellVLTAtRXF1dTFacmVLUmptUVpDSkxGX0MtY2hCY2l3ajU4M25SMG95OHdlc1RHN1dmaHZZMF9uQ0o3R1FBa0NzQUtZMjIzMjU1bmttbGZsZUplQkd5Vmd2NEJoQ0NnbVhmVXppdWhiQkdpcGpQVFJVSHRBXy1pbnFJbXI0R2w3MmlvMEdCY2dGYVE4cWY2MENmeEp1ME9mZEFqSDVtdThTMk9kbUhIdXMtR0k?oc=5", "source_name": "Market source", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q4 Earnings: Integer Holdings (NYSE:ITGR) In The Context Of Other Medical Devices & Supplies - Specialty Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAJBVV95cUxNdFRrRlJvM3J3cGJnVEJ6ZndqMnQxWkE4Wm8zTGtPTVc0OTlLN1pwNXIyclNJMFZkcG5qQTRTWThmNm9WN0hKYXBja3N3Y20zSlkxc2JaQlpYTnAyWnpvUVBvR1JWNmVxZGhSYVlYQklMd01GeFBVNGJWOFBWYUkwYmRrM2xrSktiQWpfTkZtNG1HWThNT0tqLUpYek5qcnFWMGE0QV9CaElrMUpfTEhnOC1pS2t1bkE2VVJHdEhWdEtoX2xKNE1MWk1OSlBSNTVZVU83WEpnb3E4aURwQ3ZyZUFDbndpTTZEa0lZRTJvU2VuTDhreXdCQ25iV3Y4YWxENm1xYQ?oc=5", "source_name": "StockStory", "published_at": "2026-03-16T07:00:00+00:00", "published_display": "16 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highs And Lows: Abbott Laboratories (NYSE:ABT) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxPeVpVN2I3X3lJNXd3TXJmRWV4X0RvRDdYR3l5a1k1SjMxUlhsWHdrUUNuZ1JIaUg4czdhZlA2VDVIallROFFuNmZXcnNzS1d3Vm0wS0tLMmlFVWdkUThsRDZYdTdZV3k3WkRjaUZSMUQ3dkRKYm5ZOVBjMVVBdTRjYQ?oc=5", "source_name": "Market source", "published_at": "2026-03-12T07:00:00+00:00", "published_display": "12 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Pulmonx Corporation (LUNG) Releases Q4 2025 Earnings: Revenue Down, Diluted Loss Per Share Widens", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxPUlpaMzRlODlxcHZsUmxCSE9rZFBNZVM1ZWprRHlEWXlMMmh6WldDSm5sZTlvZUNtSjZmd0NSTERjdFhrVDVONDVuUzU2TGNFaWZaZHRpb3FiQmhhZEdEcjUtVnhNZl81Z05WSXhuaWpueWMzUTJXQWdHUW1zWlZzSG5VblVmWWRQanpnTG8xX013QXNMQnhnNEtvMHE1d1VSS21PSldPRXVYbGpFV0FHLS01MGhLbl9oVl9rdnQ0WldKby1qM1BOMXN3?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q4 Earnings: Enovis (NYSE:ENOV) In The Context Of Other Medical Devices & Supplies - Specialty Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxNMzBPcXU1cnZKekZnaGlNVk05ZWFTWThNOS0tTlpvQjdaLVZIWlVXUk50NnVoQ0pPWWJpZUpWcVJyVDJMd2RJREVDbEEzTlU5UGhBbWtxWVEyVkdaMTVuNXZpaWFMNTZUQ2d0OW9Rc29kalJRY21naWlHZDBLS3RuZV9wdTdIUQ?oc=5", "source_name": "Market source", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highs And Lows: Baxter (NYSE:BAX) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxOb3BiQVNFREdNblk2QS10b1lhRUtfb05vU2VFZHB5V0hJT0R4NmhwQWRrcFVsR3UwMjZleFV6N2FEelpZVzY3YWFxSWE1cWpLaTFrQVU4NktkQUloUkxaV3ZTVkh6b1ZmaDdMN2ViX1BUNE4xUTNUZFNlR0syVGlZSg?oc=5", "source_name": "Market source", "published_at": "2026-03-02T08:00:00+00:00", "published_display": "02 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Pulmonx Corporation (NASDAQ:LUNG) Not Doing Enough For Some Investors As Its Shares Slump 29%", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-11T08:00:00+00:00", "published_display": "11 Feb 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Pulmonx (NASDAQ:LUNG) Have A Healthy Balance Sheet?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-10T08:00:00+00:00", "published_display": "10 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmonx (LUNG) Stock Price, News & Analysis $LUNG", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE9YdDNVZ3FEUWFkR0x5U2ExN2otSEZLQmkwM3RNLVlVcV9SZkYybWpMNmJuVHRtM3JnOEFsU2lYU2lBaFAteGE3ZWFQTGJzZk1GeTUyY19ybXRaQQ?oc=5", "source_name": "MarketBeat", "published_at": "2020-10-10T07:38:51+00:00", "published_display": "10 Oct 2020 07:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Pulmonx to Report Second Quarter 2026 Financial Results on July 29, 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxPemxweWlKeDByaklqVm5tNlMxVGZfT05Db0hWbkJBb0E5ZVlaeHUwN0hUZDY0cUplcmljdWx0TzZ0MzFKcjhPSDJMQ1V2OTdub2dBNEY3cmRKM1RnOEtIMzdLTEVOMEtYbWduOUhaMjJ3NElrbGd5cXYtWTYyREVzWmF1bldxUnZRczhiby1ycUIwZW9uZUVNcE9JQ0dOc1FKZzFyWEc5NktiTHg1UFBnQlhuV0hoZDVuSkd4RkNlZlJIdw?oc=5", "source_name": "marketscreener.com", "published_at": "2026-07-15T20:05:05+00:00", "published_display": "15 Jul 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmonx Sets July 29 Webcast to Discuss Second-Quarter Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNcFhRTWNfTlZGY2gtZUIzaWxSMFkwTHVMaVcxZkpkQm5rQXppVmVMY0dVUGRQS0xVOElINDY5THBHbGFHQUZaMTN4WU1qYTd4MFlYMFFGR3lLdHdCdEk5dVJDSXllZ09LNnVKVlRiYlY3RmhteWN2cnQzc0phdFM4LXRvc1ljdUdRbE9ZTnNBbjc3cU1seUhxZEEtT3JHWjZXVVNIdG5MX3c2RlNvSU9ZaEoyWlBOZFdseGQzWEZ3?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T20:05:00+00:00", "published_display": "15 Jul 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Yun-Lung Chen Sells 5,958 Shares of Ambarella (NASDAQ:AMBA) Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxQbTRSd0JCZFZEcWxoSF9pWmkzNW9KNVhuQXNBaGJZUW10QjJuUjF1SjhOcXFrYm56RkI4N2w4WlZURWpROE5NbUxHY043RTZmNjg2OHkwS0NNRlN0ZlppSkwyVlJyRktpemtYQ2JjSWZmelBFS1hOVlNEMjZDWTd4Nm1UclVKd2MwbGFsUGxoX3Fhb0ZXTUpScmtDM2w2Wm0wMVJHbVRjNlpKbTk5YTRFYmlaeVdlQQ?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-10T21:09:06+00:00", "published_display": "10 Jul 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmonx (NASDAQ:LUNG) Sparks Fresh Penny Stock Buzz", "summary": "Pulmonx (NASDAQ:LUNG) is attracting attention as a penny stock due to its focus on severe emphysema treatment. The company's key products, the Zephyr Endobronchial Valve and the Chartis system, are highlighted for their role in improving lung function in affected patients. This r", "url": "https://kalkinemedia.com/us/stocks/penny/pulmonx-nasdaqlung-sparks-fresh-penny-stock-buzz", "source_name": "Kalkine Media", "published_at": "2026-07-09T20:45:19", "published_display": "09 Jul 2026 20:45", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmonx Corp highlights lung device strategy as a specialized medtech player", "summary": "Pulmonx Corp positions itself as a specialized medical technology company focusing on minimally invasive devices for severe emphysema and chronic respiratory conditions. Its business model centers on bronchoscopic procedures, generating revenue from implantable devices and associ", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/pulmonx-corp-highlights-lung-device-strategy-as-a-specialized-medtech/69716357", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T19:32:00", "published_display": "07 Jul 2026 19:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Pulmonx Corp. \u2013 LSX:A2P1AF", "summary": "This page from TradingView provides financial information for Pulmonx Corp. under the ticker LSX:A2P1AF. It focuses on the enterprise value to EBITDA forward metric, but the actual data values are not visible in the provided content. The page also includes various navigation and ", "url": "https://www.tradingview.com/symbols/LSX-A2P1AF/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T06:09:24", "published_display": "05 Jul 2026 06:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Pulmonx Corp. \u2013 LSX:A2P1AF", "summary": "This article focuses on the \"Enterprise value to EBIT forward\" metric for Pulmonx Corp. (LSX:A2P1AF). It appears to be a financial data snippet from TradingView, providing an overview of a specific valuation ratio for the company's stock. The content points to financial data avai", "url": "https://www.tradingview.com/symbols/LSX-A2P1AF/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T04:39:39", "published_display": "05 Jul 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Pulmonx Corp. \u2013 LSX:A2P1AF", "summary": "This article provides the \"Price to earnings forward\" valuation metric for Pulmonx Corp. (LSX:A2P1AF). It indicates the value and change of this financial data point over a period. The information is presented within the context of TradingView's platform, which offers various fin", "url": "https://www.tradingview.com/symbols/LSX-A2P1AF/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T02:10:12", "published_display": "05 Jul 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Pulmonx Corp. \u2013 DUS:4NI", "summary": "This article provides the \"Price to earnings forward\" data for Pulmonx Corp. (DUS:4NI) on the TradingView platform. It details the company's financial information, presented within the context of the D\u00fcsseldorf Stock Exchange. The content is primarily a data page on a financial p", "url": "https://www.tradingview.com/symbols/DUS-4NI/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T01:39:39", "published_display": "05 Jul 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Pulmonx Corp. \u2013 DUS:4NI", "summary": "This page from TradingView provides financial information for Pulmonx Corp. (4NI) listed on the Dusseldorf Stock Exchange, specifically focusing on its forward price-to-sales ratio. The article includes standard market data and copyright information, indicating that the market fo", "url": "https://www.tradingview.com/symbols/DUS-4NI/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T01:10:12", "published_display": "05 Jul 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmonx Corp highlights its respiratory device portfolio as investors assess long-term growth prospects", "summary": "Pulmonx Corp (PULM) focuses on developing minimally invasive medical devices for severe emphysema and other chronic obstructive pulmonary diseases, targeting a significant unmet medical need. The company's business model involves selling specialized devices to healthcare provider", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/pulmonx-corp-highlights-its-respiratory-device-portfolio-as-investors/69681305", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-03T15:40:31", "published_display": "03 Jul 2026 15:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmonx Corp. Actuals & Estimates (NASDAQ:LUNG)", "summary": "This article provides financial actuals and estimates for Pulmonx Corporation (NASDAQ: LUNG), including its current stock price, historical performance, analyst forecasts, and company financials. It details the company's market capitalization, last quarter's earnings and revenue,", "url": "https://www.tradingview.com/symbols/NASDAQ-LUNG/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T01:11:28", "published_display": "26 Jun 2026 01:11", "sentiment": "negative", "sentiment_pct": 30, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmonx Corp (LUNG) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Pulmonx Corp (LUNG) has a stable financial status but low operating efficiency, ranking 142 out of 204 in the Healthcare Equipment & Supplies industry with a financial score of 6.69. The company's latest quarterly revenue decreased by 8.66% year-over-year to $20.59 million, and i", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lung/financial-health", "source_name": "TradingKey", "published_at": "2026-06-23T23:40:47", "published_display": "23 Jun 2026 23:40", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmonx Corp (LUNG) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Pulmonx Corp (LUNG), highlighting its price momentum score of 5.32 within the Healthcare Equipment & Supplies industry. It details the stock's current trading range between a resistance level of $1.59 and a support level of $1.09, sug", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lung/technical", "source_name": "TradingKey", "published_at": "2026-06-18T22:09:19", "published_display": "18 Jun 2026 22:09", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmonx Corp (LUNG) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Pulmonx Corp (LUNG), highlighting its current earnings forecast score, average price target of $4.50, and analyst ratings. Based on 5 analysts, the stock has a \"Buy\" trend. The article also includes expected revenue and EPS for upcom", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lung/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T11:09:47", "published_display": "18 Jun 2026 11:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmonx Corp (LUNG) Institutional Confidence", "summary": "Pulmonx Corp (LUNG) has an institutional shareholding score of 7.00, placing it 79th out of 204 in the Healthcare Equipment & Supplies industry. The institutional shareholding proportion increased by 10.02% quarter-over-quarter to 87.40%. James Simons is noted as the largest inst", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lung/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T11:09:47", "published_display": "18 Jun 2026 11:09", "sentiment": "positive", "sentiment_pct": 69, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmonx Corp (LUNG) Valuation: PE, PB & Fair Value Analysis", "summary": "The article provides a valuation analysis for Pulmonx Corp (LUNG), noting its current valuation score is 7.71, ranking 137 out of 204 in the Healthcare Equipment & Supplies industry. It highlights the company's P/E ratio of -0.97, which represents a decrease from its recent high ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lung/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T10:09:48", "published_display": "18 Jun 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmonx Corp (LUNG) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a revenue breakdown for Pulmonx Corp (LUNG), detailing its revenue by geographical region for the fiscal year 2023. The United States contributed the largest portion of revenue at 63.01% ($57.02 million), followed by Europe, Middle-East and Africa (\"EMEA\") a", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lung/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T21:09:21", "published_display": "17 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmonx Corp (LUNG) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Pulmonx Corp's (LUNG) dividend and stock split history, noting that no dividend data or stock split data is available. It shows the current stock price, market cap, and links to various company and market analysis sections on the TradingKey pl", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lung/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T21:09:21", "published_display": "17 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Pulmonx Corp Insider Trading Activity", "summary": "Pulmonx Corp director Thomas William Burns has been granted 40,000 Restricted Stock Units (RSUs) as compensation, not through a market purchase. These RSUs, valued at $0.0000 per share, will vest on the earlier of one year from the June 5, 2026 grant date or the date of the Annua", "url": "https://www.stocktitan.net/sec-filings/LUNG/form-4-pulmonx-corp-insider-trading-activity-a7293e34ec44.html", "source_name": "Stock Titan", "published_at": "2026-06-10T18:39:13", "published_display": "10 Jun 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmonx (LUNG) director receives 40,000-share RSU stock grant", "summary": "Pulmonx Corp director Dana G. Mead Jr. was granted 40,000 Restricted Stock Units (RSUs) which are payable in common stock. This is an equity compensation award, not an open-market purchase, with a grant price of $0.00 per share. These RSUs will vest on the earlier of June 5, 2026", "url": "https://www.stocktitan.net/sec-filings/LUNG/form-4-pulmonx-corp-insider-trading-activity-7432e390c79e.html", "source_name": "Stock Titan", "published_at": "2026-06-10T06:40:14", "published_display": "10 Jun 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LUNG SEC Filings - Pulmonx Corp 10-K, 10-Q, 8-K Forms", "summary": "This page provides access to SEC filings for Pulmonx Corporation (LUNG), a medical technology company. It includes 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider trading forms. The filings detail the company's financial results, governance, compensa", "url": "https://www.stocktitan.net/sec-filings/LUNG/page-5.html", "source_name": "Stock Titan", "published_at": "2026-06-10T03:39:51", "published_display": "10 Jun 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Don't Ignore The Insider Selling In Pulmonx", "summary": "Pulmonx Corporation's CEO and President, Glendon French, recently sold US$87k worth of stock at US$1.55 per share, following an earlier sale of US$97k below the current price. Insiders own 5.1% of Pulmonx shares, worth approximately US$3.3m, but there have been no insider purchas", "url": "https://www.sahmcapital.com/news/content/dont-ignore-the-insider-selling-in-pulmonx-2026-06-07", "source_name": "Sahm", "published_at": "2026-06-07T22:11:00", "published_display": "07 Jun 2026 22:11", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmonx (LUNG) officer sells 14,497 shares to cover RSU tax withholding", "summary": "Pulmonx Corp's Chief Science & Technology Officer, Radhakrishnan Srikanth, sold 14,497 shares of common stock on June 1, 2026, across four transactions at $1.54 per share. These sales totaling $22,325 were made exclusively to cover tax withholding obligations stemming from the ve", "url": "https://www.stocktitan.net/sec-filings/LUNG/form-4-pulmonx-corp-insider-trading-activity-533f2da6b3c1.html", "source_name": "Stock Titan", "published_at": "2026-06-04T16:09:33", "published_display": "04 Jun 2026 16:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmonx general counsel David Lehman sells $22,474 in stock", "summary": "David Aaron Lehman, General Counsel at Pulmonx Corp, sold 14,594 shares of company stock worth $22,474 on June 1, 2026, to cover tax obligations from vested RSUs. This transaction occurred as Pulmonx faces financial challenges, including quickly burning through cash and remaining", "url": "https://m.uk.investing.com/news/insider-trading-news/pulmonx-general-counsel-david-lehman-sells-22474-in-stock-93CH-4712760?ampMode=1", "source_name": "Investing.com UK", "published_at": "2026-06-04T04:40:11", "published_display": "04 Jun 2026 04:40", "sentiment": "negative", "sentiment_pct": 30, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmonx (LUNG) CCO sells shares to cover RSU tax obligations", "summary": "Pulmonx Corp's Chief Commercial Officer, Geoffrey Beran Rose, sold 8,023 shares of common stock at $1.54 per share on June 1, 2026. These sales were conducted to cover tax withholding obligations associated with the vesting of his Restricted Stock Units from 2023, 2024, 2025, and", "url": "https://www.stocktitan.net/sec-filings/LUNG/form-4-pulmonx-corp-insider-trading-activity-a3a1fee41177.html", "source_name": "Stock Titan", "published_at": "2026-06-03T20:09:29", "published_display": "03 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmonx (LUNG) General Counsel sells 14,594 shares to cover RSU tax obligations", "summary": "Pulmonx Corp General Counsel David Aaron Lehman sold 14,594 shares of common stock at $1.54 per share on June 1, 2026. These sales were executed in four transactions solely to cover tax withholding obligations arising from the vesting of Restricted Stock Units granted between 202", "url": "https://www.stocktitan.net/sec-filings/LUNG/form-4-pulmonx-corp-insider-trading-activity-6f9d8660cef2.html", "source_name": "Stock Titan", "published_at": "2026-06-03T20:09:29", "published_display": "03 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmonx (LUNG) CEO logs 56K-share sale tied to RSU tax withholding", "summary": "Pulmonx Corp CEO Glendon E. French III sold 56,149 shares of common stock on June 1-2, 2026, at prices between $1.54 and $1.57 per share. These sales were made to cover tax withholding obligations related to the vesting of Restricted Stock Units (RSUs) granted on March 1, 2023, a", "url": "https://www.stocktitan.net/sec-filings/LUNG/form-4-pulmonx-corp-insider-trading-activity-cb3a2e50bf58.html", "source_name": "Stock Titan", "published_at": "2026-06-03T20:09:29", "published_display": "03 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "17 Pulmonx hires receive 84,300 RSUs in Nasdaq inducement plan", "summary": "Pulmonx (Nasdaq:LUNG) has granted equity awards totaling 84,300 Restricted Stock Units (RSUs) to 17 new employees hired in the first two quarters of 2026. These awards, issued under its 2025 Inducement Plan, are subject to a four-year vesting schedule, with one-fourth vesting on ", "url": "https://www.stocktitan.net/news/LUNG/pulmonx-corporation-announces-inducement-grants-under-nasdaq-listing-zj3qliqrqhkw.html", "source_name": "Stock Titan", "published_at": "2026-06-02T15:09:50", "published_display": "02 Jun 2026 15:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "Pulmonx Corporation announced that it granted equity awards to 17 new employees on June 1, 2026, under its 2025 Inducement Plan. These awards, totaling 84,300 restricted stock units, were approved by the Compensation Committee as an inducement for employment, in compliance with N", "url": "https://www.manilatimes.net/2026/06/02/tmt-newswire/globenewswire/pulmonx-corporation-announces-inducement-grants-under-nasdaq-listing-rule-5635c4/2356240/amp", "source_name": "The Manila Times", "published_at": "2026-06-01T20:09:01", "published_display": "01 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmonx (LUNG) Q1 2026 Earnings Transcript", "summary": "", "url": "https://finance.yahoo.com/m/20552afe-2c36-3531-a10b-e88c4489fc7f/pulmonx-%28lung%29-q1-2026.html", "source_name": "Motley Fool", "published_at": "2026-04-30T16:25:20+00:00", "published_display": "30 Apr 2026 16:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmonx Corporation Q1 2026 Earnings Call Summary", "summary": "", "url": "https://finance.yahoo.com/m/b0a2f218-62a9-3f4f-a795-a3e923c01a95/pulmonx-corporation-q1-2026.html", "source_name": "Moby", "published_at": "2026-04-30T12:30:00+00:00", "published_display": "30 Apr 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmonx Corp (LUNG) Q1 2026 Earnings Call Highlights: Navigating Challenges with Strategic ...", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/pulmonx-corp-lung-q1-2026-071730915.html", "source_name": "GuruFocus.com", "published_at": "2026-04-30T07:17:30+00:00", "published_display": "30 Apr 2026 07:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmonx Q1 Earnings Call Highlights", "summary": "", "url": "https://finance.yahoo.com/m/b6392ff6-2067-3349-9cf8-609646793e13/pulmonx-q1-earnings-call.html", "source_name": "MarketBeat", "published_at": "2026-04-29T21:50:17+00:00", "published_display": "29 Apr 2026 21:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmonx Corporation (LUNG) Reports Q1 Loss, Tops Revenue Estimates", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/pulmonx-corporation-lung-reports-q1-214506050.html", "source_name": "Zacks", "published_at": "2026-04-29T21:45:06+00:00", "published_display": "29 Apr 2026 21:45", "sentiment": "negative", "sentiment_pct": 42, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmonx Reports First Quarter 2026 Financial Results", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/pulmonx-reports-first-quarter-2026-200500616.html", "source_name": "GlobeNewswire", "published_at": "2026-04-29T20:05:00+00:00", "published_display": "29 Apr 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmonx Corporation (LUNG) Stock Falls on Q1 2026 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxPZWM5SnJLbEpRTWNfRFM5SW9sMlVsV3E1U2VPNW1OcTV1Y1VmdkI4eVdNWnpjX0tCY29TcDhOWWJoWlQwQmtjVUdsejl5YXpoNGR3MHhVd19MR0xBZXBicmI4T1lxSjVkNTlxZmFjcHdmVi1NN09aRDZXZHd0UzBYVGxOYVJob3R4bi1WNTd2RWRPcU5IeXc?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 22, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmonx to Present at the Bank of America Securities 2026 Health Care Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/pulmonx-present-bank-america-securities-200500916.html", "source_name": "GlobeNewswire", "published_at": "2026-04-28T20:05:00+00:00", "published_display": "28 Apr 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmonx to Detail Growth Strategy at Key Investor Conference", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxQSE5OQXlJd2o5VkVyZ0VWQW9HQjA0QlVEeHc2ZzhfLUtfa05PUFFkMGo1dmg0RDE0M0dfcDM5LVZIcUNlcGJqN2toRDR0NlI1NzdsTkppTU52djBPMjFZOWdCYUdWemJQRzdGc0VlM2xndXdPS0U3bzd0NDRJN2tfVzY0MHhJeGRqR0JWbGEtYWtMbnJxclVhOQ?oc=5", "source_name": "BriefGlance", "published_at": "2026-04-28T07:00:00+00:00", "published_display": "28 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmonx webcast set for May 12 Bank of America health conference", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOYy05MTYzMlpRVG1BYVU1djBTcnc4YVNrUGN4NVh4SWNJb2JRSzMteEpuTlNDalJqZU12YlNzSEpIVnFtelhlbmxtSUJpMEJWMWlqZ3VTY0xuemw5ZzRua3M5NXBLOWhLbExpNXFRSFB6dzMwOTdyWEtjT2dLckRpWi1pc1k5VHVicVpKcGdqc3BYUnBabkNHQ3pyQTFoT2dwSFotN2VQR0lVemZEb0RaX08tLXV5TE5qbjZN?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-28T07:00:00+00:00", "published_display": "28 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Pulmonx (LUNG) Investment Narrative Is Resetting Around A Lower Target And Execution Risk", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/pulmonx-lung-investment-narrative-resetting-150530295.html", "source_name": "Simply Wall St.", "published_at": "2026-04-19T15:05:30+00:00", "published_display": "19 Apr 2026 15:05", "sentiment": "negative", "sentiment_pct": 34, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Pulmonx (LUNG) Investment Story Is Shifting After Q4 And New Guidance", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNSHo4SFM5NzJrbEI1OC1HazJXOXBLT3hhTldYZDY1NWpiLWlIR00zR2xNWmZybDh1YmZmTTlnTjRqM1VRRlB0SlY0VmY2dHA0Z3JZd2tVM282X1dVUGtHUWQ2RzV4OXJxVE02UDc3TG1wdlhKVGlKamptR3BuUGhuWVRnemdnSkZYTnBTUXJIVjFPZHRyc3ZIVmFqWTJobGQxS1hvaWR3?oc=5", "source_name": "Market source", "published_at": "2026-04-04T07:00:00+00:00", "published_display": "04 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmonx Corporation (LUNG) Releases Q4 2025 Earnings: Revenue Down, Diluted Loss Per Share Widens", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxPUlpaMzRlODlxcHZsUmxCSE9rZFBNZVM1ZWprRHlEWXlMMmh6WldDSm5sZTlvZUNtSjZmd0NSTERjdFhrVDVONDVuUzU2TGNFaWZaZHRpb3FiQmhhZEdEcjUtVnhNZl81Z05WSXhuaWpueWMzUTJXQWdHUW1zWlZzSG5VblVmWWRQanpnTG8xX013QXNMQnhnNEtvMHE1d1VSS21PSldPRXVYbGpFV0FHLS01MGhLbl9oVl9rdnQ0WldKby1qM1BOMXN3?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmonx Corporation (NASDAQ:LUNG) Not Doing Enough For Some Investors As Its Shares Slump 29%", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-11T08:00:00+00:00", "published_display": "11 Feb 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Pulmonx (NASDAQ:LUNG) Have A Healthy Balance Sheet?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-10T08:00:00+00:00", "published_display": "10 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pulmonx (LUNG) Stock Price, News & Analysis $LUNG", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE9YdDNVZ3FEUWFkR0x5U2ExN2otSEZLQmkwM3RNLVlVcV9SZkYybWpMNmJuVHRtM3JnOEFsU2lYU2lBaFAteGE3ZWFQTGJzZk1GeTUyY19ybXRaQQ?oc=5", "source_name": "MarketBeat", "published_at": "2020-10-10T07:38:51+00:00", "published_display": "10 Oct 2020 07:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Reflecting On Medical Devices & Supplies - Specialty Stocks\u2019 Q1 Earnings: Integer Holdings (NYSE:ITGR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNUFd1SUpRcWlCdEFjU1YzNTZkdjBfRkwyY2lBYjh1ZXZlZTlyVlpWSWx1bExvckFrNHNhUEdVTGNFWUxaMkVDZUV2c2hPS1h2YVhNSHNsVzFYNUFrNHBnRVM1STRsa2Zmb0VXeEQ4UFRGNDBOWXZfWVU5VFUyQ3JZZm9KamZMWXVDSEtNMWwyVktpaEZfRjVNU1BYaWJ3NnpNUmRyMEpsSzBXdw?oc=5", "source_name": "Market source", "published_at": "2026-07-14T18:07:11+00:00", "published_display": "14 Jul 2026 18:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks Q1 Earnings: ICU Medical (NASDAQ:ICUI) Firing on All Cylinders", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNTWR3bzJReVB0UTNleWx6WDlmRW1rYmpLdkptZHdadzVERk1hTzdEV0M1Z2tuRUx2cldOT2d3WlVDank5Y01EWWFfWXdWNkJFdkNFcnhjMjdCQ1Y2aFBVbndiNXVBY0F5dDRpU2Fla25fVWRTUlNROXFwYXNXT2czUm5Nbl9QUFhFTEhHd1ZKTzJUSzhJWjN6QnNNUEVBTVEyR0l6YkZacUVsdw?oc=5", "source_name": "Market source", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q1 Earnings Review: Medical Devices & Supplies - Diversified Stocks Led by Baxter (NYSE:BAX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNYjhBT3BjMWFVU1FFUUFub0d6QUVEUTdwWFVMRG5fN2dHSnIxTXQwMWU1aElKaEV1a2dYLTFHMlBzMVFTZEtaX0xRRDFhZDl1WFdDYWF2RDZxOG9SRUtycmZacTRzM2FaaEU3OS1GZ2taLWtSMjZ4enhVNHRvdzJsanp4cEhNcGI1dllTOUplWUUtNjRlRm85MlFEVWxSYUV2d243QVd3?oc=5", "source_name": "Market source", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Medical Devices & Supplies - Diversified Stocks Q1 Results: Benchmarking Stryker (NYSE:SYK)", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxNb1NaVXV6UW42emtDUzh5ckhKVjc2X29fSlFRRDVIVnRLWXpoWEYxUnVKNGZuLVN6ZWhxVno1SGluMEdLcmNrOGN1ZjlsWFpVRWxYbW9aYy01VFFpVzlncWtBYzF3YkJfNzhwTi1BcWlpVF9pUTU4QnNGWkJSV3YwRXVCUzk2Z2NUMWFjVkJOV2hSbFRrRnIxSWxNUGRoQmhQeDVBRjhYSnhvMDJqUThjYjBHRjhTRTBDdDZJd1k3LU5DTjU2cUx6TXFNdHhVS1FfdlFmaWZLNk41cFk?oc=5", "source_name": "StockStory", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Medical Devices & Supplies - Specialty Q4 Earnings: Globus Medical (NYSE:GMED) is the Best in the Biz", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNcDFMNmtOVk5PVFM1YzMyVWhyS3dwY0dMVE5BUng5U1JoOFRQMXNFRGxTMmlBRUV0bENRSWFXTDFZOXBQQkNZT0FOWDdISjRCcU9pRV9aNHBwUVBuZkVEV3g1dklVY19KOE9iWUNpNUtMS2NuOEcxMlQtNU8ydURybEdkNVoxZThWLTBIeVhid2NjQ0FWWTUzb2dxcmlMQThFQmZ4bldzRjcwUQ?oc=5", "source_name": "Market source", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Medical Devices & Supplies - Imaging, Diagnostics Stocks\u2019 Q4 Earnings: Hologic (NASDAQ:HOLX) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOdkl6Ym5HSGVhZUw3TzNlNVFPSjdDQk5NMTVSRW1xVnh3RE5RNU9veVR0TDEtcVdxV3BYelI0bWxCYXgwWmhZQ3ZONUVRdlhjX0ZiMklRVDJQRXN0LXcyVWVnb0E2WTdiRERtZk1pNGpmVHhWbHl5eHJuNnBtTDVPMUluTmRsQUVqYjNlSl8zR3djclh0X2ZIc1gzTlhPanR6ZTJ6R1FB?oc=5", "source_name": "Market source", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Artivion (NYSE:AORT) Vs The Rest Of The Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPaTgxS3dlMlZ5dDZ3dFlGdG9yRWFubkVqMk9yOTN6OEtyemljTWJGYUcxb2pmd2FTNTFKMlhIVGxrdlJsOG5iY1VQaXE4ZmYycTVpRkE0aEJ3QlB5bC10ZXN2dTFYNy0wRWdrNURVUlo5dEMzQklxQ0kwQTRkOXE0UDdTMkRGRWxoQ1ZQeG4tOXNONlR2SkxfZW5ST1B6N3BBeFZZQ3N1UFE?oc=5", "source_name": "Market source", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: CooperCompanies (NASDAQ:COO) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOellVLTAtRXF1dTFacmVLUmptUVpDSkxGX0MtY2hCY2l3ajU4M25SMG95OHdlc1RHN1dmaHZZMF9uQ0o3R1FBa0NzQUtZMjIzMjU1bmttbGZsZUplQkd5Vmd2NEJoQ0NnbVhmVXppdWhiQkdpcGpQVFJVSHRBXy1pbnFJbXI0R2w3MmlvMEdCY2dGYVE4cWY2MENmeEp1ME9mZEFqSDVtdThTMk9kbUhIdXMtR0k?oc=5", "source_name": "Market source", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q4 Earnings: Integer Holdings (NYSE:ITGR) In The Context Of Other Medical Devices & Supplies - Specialty Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAJBVV95cUxNdFRrRlJvM3J3cGJnVEJ6ZndqMnQxWkE4Wm8zTGtPTVc0OTlLN1pwNXIyclNJMFZkcG5qQTRTWThmNm9WN0hKYXBja3N3Y20zSlkxc2JaQlpYTnAyWnpvUVBvR1JWNmVxZGhSYVlYQklMd01GeFBVNGJWOFBWYUkwYmRrM2xrSktiQWpfTkZtNG1HWThNT0tqLUpYek5qcnFWMGE0QV9CaElrMUpfTEhnOC1pS2t1bkE2VVJHdEhWdEtoX2xKNE1MWk1OSlBSNTVZVU83WEpnb3E4aURwQ3ZyZUFDbndpTTZEa0lZRTJvU2VuTDhreXdCQ25iV3Y4YWxENm1xYQ?oc=5", "source_name": "StockStory", "published_at": "2026-03-16T07:00:00+00:00", "published_display": "16 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highs And Lows: Abbott Laboratories (NYSE:ABT) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxPeVpVN2I3X3lJNXd3TXJmRWV4X0RvRDdYR3l5a1k1SjMxUlhsWHdrUUNuZ1JIaUg4czdhZlA2VDVIallROFFuNmZXcnNzS1d3Vm0wS0tLMmlFVWdkUThsRDZYdTdZV3k3WkRjaUZSMUQ3dkRKYm5ZOVBjMVVBdTRjYQ?oc=5", "source_name": "Market source", "published_at": "2026-03-12T07:00:00+00:00", "published_display": "12 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q4 Earnings: Enovis (NYSE:ENOV) In The Context Of Other Medical Devices & Supplies - Specialty Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxNMzBPcXU1cnZKekZnaGlNVk05ZWFTWThNOS0tTlpvQjdaLVZIWlVXUk50NnVoQ0pPWWJpZUpWcVJyVDJMd2RJREVDbEEzTlU5UGhBbWtxWVEyVkdaMTVuNXZpaWFMNTZUQ2d0OW9Rc29kalJRY21naWlHZDBLS3RuZV9wdTdIUQ?oc=5", "source_name": "Market source", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highs And Lows: Baxter (NYSE:BAX) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxOb3BiQVNFREdNblk2QS10b1lhRUtfb05vU2VFZHB5V0hJT0R4NmhwQWRrcFVsR3UwMjZleFV6N2FEelpZVzY3YWFxSWE1cWpLaTFrQVU4NktkQUloUkxaV3ZTVkh6b1ZmaDdMN2ViX1BUNE4xUTNUZFNlR0syVGlZSg?oc=5", "source_name": "Market source", "published_at": "2026-03-02T08:00:00+00:00", "published_display": "02 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 99, "total_relevant": 58, "sentiment_summary": {"positive": 5, "negative": 10, "neutral": 43, "score": 49, "total": 58, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "earnings", "primary_label": "Earnings", "confidence": 77, "events": [{"event": "earnings", "label": "Earnings", "weight": 15.2, "count": 30}, {"event": "general", "label": "Market update", "weight": 13.2, "count": 24}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 5, "negative_events": 10}, "market_context": {"has_market_context": true, "latest_close": 1.54, "latest_week": "2026-07-10", "one_week_move": 10.8, "four_week_move": 12.4, "twelve_week_move": 4.8, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.774339, "market_dynamics_buy_signal": false, "relative_strength": -23.302751, "fair_value_gap": -74.1, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 48.0648, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+10.8% over one week, +12.4% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 58, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Earnings", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 11}, {"label": "Stock Titan", "count": 10}, {"label": "TradingKey", "count": 7}, {"label": "TradingView", "count": 6}, {"label": "MarketBeat", "count": 3}, {"label": "StockStory", "count": 2}, {"label": "GlobeNewswire", "count": 2}, {"label": "Quiver Quantitative", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 46}, {"label": "Industry context", "count": 12}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 30}, {"label": "Market update", "count": 24}, {"label": "Capital return", "count": 1}, {"label": "Balance sheet", "count": 1}, {"label": "Analyst action", "count": 1}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "49/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Earnings", "tone": "neutral", "text": "77/100 classification confidence."}, {"label": "Company focus", "value": "46", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+10.8% over one week, +12.4% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Pulmonx to Report Second Quarter 2026 Financial Results on July 29, 2026"}], "updated_at": "2026-07-16T06:04:41.538232+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}